Unum Therapeutics

Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, Unum is discovering and developing new cellular immunotherapies for cancer. The company’s vision is of a single cell therapy (‘unum’ = one) that can be applied to the treatment of many different cancers. Unum went public in March 2018 (NASDAQ: UMRX).

Headquarters Cambridge, MA
Website www.unumrx.com​
Twitter @UnumRx​
Pipeline Phase 1
Partners Seattle Genetics